2015-2019 France Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

September 2015 | 585 pages | ID: 2ACEE3534F8EN
Venture Planning Group

Abstracts

Complete report $6,800. DataPack (test volumes, sales forecasts, supplier shares) $3,450. 2015-2019 France Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the French cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Business Opportunities and Strategic Recommendations- Specific new product development opportunities with potentiallysignificant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies.

Potential market entry barriers and risks. Cancer Diagnostic Tests—Over 200 current and emerging assays including:ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27. 29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others. Market Segmentation Analysis- Sales and market shares of major suppliers, by individual cancer diagnostic test. - Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:- Hospitals- Commercial/Private Laboratories- Comprehensive market segmentation analysis, including reviewof the market dynamics, structure, size, growth and major suppliers. - Cancer statistics, etiology and recent developments. Current and Emerging Products- Review of over 200 current and emerging cancer diagnostic tests,including:- Biochemical Markers- Oncogenes- Growth Factors- Hormones- Colony Stimulating Factors- Lymphokines- Immunohistochemical Stains, and others. - Analysis of major immunoassay analyzers used forcancer diagnostic testing, including their operating characteristics,features and selling prices. Technology Review- Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Assessments- Strategic assessments ofmajor suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborativearrangements, and new products in R&D. Contains 585 pages and 95 tables

Contents

BLOOD GROUP GENOTYPING

a. PCR
b. PCRRFLP
c. ASPCR or PCRSSP
d. Multiplex PCR
e. Real Time PCR
f. Sanger DNA Sequencing
g. Pyrosequencing
b. Microarrays
  BeadChip Array
  BloodChip
  Genome Lab SNP Stream
  Fluidic Microarray Systems
  TaqMan OpenArray

MALDITOFMS

MiniSequencing

INSTRUMENTATION REVIEW

Abbott Architect i2000 Series
Abbott AxSYM
Abbott LCx
Abbott Prism
Abbott Quantum II
Beckman Coulter/Biomek FX
Beckman Coulter BloodTrack Courier
Beckman Coulter OLA2500
Beckman Coulter PK7100
Beckman Coulter PK7200
Beckman Coulter PK80
Beckman Coulter Tango
BD Viper System with XTR Technology
BD Innova
Becton Dickinson SDA
bioMerieux BacT/Alert
bioMerieux NucliSENS easyMAG
bioMerieux NucliSens EasyQ and MiniMAG
BioRad Elite
BioRad GeneScope
Cepheid GeneXpert
Curetis Unyvero
GenMark DX eSensor XT-
Grifols Diana
Hologic/GenProbe Panther
Hologic/GenProbe Tigris/DTS
HTG Molecular Edge
Immucor ABS2000
Immucor Galileo
Immucor Rosys Plato System
Life Technologies QuantStudio Dx
Nanosphere Verigen Series
Ortho AutoVue/ProVue
Ortho StarFame Combo
Ortho Summit Processor
Qiagen QIAsymphony RGQ
Roche Cobas Amplicor
Roche Cobas TaqMan
Roche Cobas TaqMan
Roche Cobas TaqMan AmpliPrep
Roche LightCycler
Roche Cobas 4800
Roche Cobas s
Sarstedt PVS
Siemens BEP 2000
Siemens Quadriga
Siemens SDA
Siemens Versant
Tecan ELPHAtyper
Tecan Genesis FE500
Tecan Hemotyper
Tecan LS Series
Tecan MegaFlex
Tecan MiniSwift

COMPETITIVE ASSESSMENTS

Abbott
Beckman Coulter/Danaher
Becton Dickinson
Biokit
BioMerieux
BioRad
CellMark Forensics/LabCorp
Diagast
DiaSorin
Fujirebio
Grifols
Hologic/GenProbe
Immucor
OrthoClinical Diagnostic
Proteome Sciences
Quest
Quidel
Roche
Siemens
Tecan
Thermo Fisher